Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;46(3):540-557.
doi: 10.1007/s00259-018-4207-9. Epub 2018 Dec 5.

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Ian Law  1 , Nathalie L Albert  2 , Javier Arbizu  3 , Ronald Boellaard  4   5 , Alexander Drzezga  6 , Norbert Galldiks  7   8 , Christian la Fougère  9 , Karl-Josef Langen  8   10 , Egesta Lopci  11 , Val Lowe  12 , Jonathan McConathy  13 , Harald H Quick  14 , Bernhard Sattler  15 , David M Schuster  16 , Jörg-Christian Tonn  17 , Michael Weller  18
Affiliations

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Ian Law et al. Eur J Nucl Med Mol Imaging. 2019 Mar.

Abstract

These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.

Keywords: FDG; FDOPA; FET; Glioma; MET; PET.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The following authors declare that they have no conflicts of interest: Nathalie L Albert, Norbert Galldiks, Karl-Josef Langen, Egesta Lopci, Bernhard Sattler, Michael Weller.

Ian Law has received a speaker honorarium from Siemens Healthcare; Javier Arbizu has received research grants from Lilly-Avid, General Electric Healthcare and Piramal, and speaker honoraria from Biogen, Araclon Biotech-Grifols, Bayer and Novartis; Ronald Boellaard has received research grants from Philips Healthcare, Siemens Healthcare, BMS and Roche, and speaker honoraria from Philips Healthcare and Siemens Healthcare; Alexander Drzezga has received research grants from Siemens Healthcare and Lilly-Avid, and a speaker honorarium from Siemens Healthcare, owns stock in Siemens Healthcare, and is a member of an advisory committee for GE Healthcare; Christian la Fougère has received research grants from GE Healthcare and a speaker honorarium from GE Healthcare; Val Lowe has been a consultant for Bayer Schering Pharma, Piramal Life Sciences and Merck Research, and has received research support from GE Healthcare, Siemens Molecular Imaging and AVID Radiopharmaceuticals; Jonathan McConathy has received research support and has been a consultant for Blue Earth Diagnostic; Harald H. Quick has received research grants from Siemens Healthcare; David M. Schuster has received research grants from Blue Earth Diagnostics, Nihon MediPhysics Co. Ltd. and Advanced Accelerator Applications, and is a consultant for Syncona and American Imaging Management; Jörg-Christian Tonn has received research grants and a speaker honorarium from BrainLab, and owns stock in Johnson and Johnson.

Ethical approval

These guidelines do not describe any studies with human participants or animals performed by any of the authors.

Approval

These practice guidelines were approved by the Board of Directors of the EANM, SNMMI, EANO and PET RANO.

Comment in

References

    1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62. - PMC - PubMed
    1. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–e329. - PubMed
    1. Reardon DA, Ballman KV, Buckner JC, Chang SM, Ellingson BM. Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014;16(Suppl 7):vii24–vii35. - PMC - PubMed
    1. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534–e542. - PMC - PubMed
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010;28:1963–1972. - PubMed